http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106536753-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2015-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-106536753-B |
titleOfInvention | Methods for determining responsiveness to MEK/ERK inhibitors |
abstract | The present invention provides a method for predicting the responsiveness of cancer cells to MEK inhibitors, the method comprising detecting one or more genes selected from the group consisting of ADAM12, COL14A1, TNN and TP53 in the cancer cells The presence of at least one mutation. The present invention also provides a method for predicting the responsiveness of cancer cells to ERK inhibitors, the method comprising detecting one or more genes selected from the group consisting of ADAM12, PEX5L, TNN and TP53 in the cancer cells presence of at least one mutation in |
priorityDate | 2014-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 963.